Laser surgery, Optune device, and Keytruda for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your glioblastoma has come back or grown despite previous treatment
- You can care for yourself with some help (Karnofsky score of 60% or higher)
- Your tumor is in a spot where MRI-guided laser ablation and the Optune device can be used safely
- You have not taken bevacizumab (Avastin) or certain immunotherapy drugs before
- You don't have active bleeding in the brain or a condition that requires blood thinners
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial combines two immunotherapy drugs (ipilimumab and nivolumab) given through a vein and directly into the brain for people with recurrent glioblastoma. The goal is to see if this approach can help control the tumor.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This trial tests a new approach that combines a drug (SONALA-001 or 5-ALA) with focused ultrasound to treat glioblastoma that has come back or is growing despite standard treatments. The drug makes tumor cells sensitive to sound waves, and the ultrasound waves are directed at the tumor using MRI guidance. This may help damage cancer cells while sparing healthy brain tissue.
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.